BAFNAPH vs GLAXO: Stock Comparison
Bafna Pharmaceuticals Limited vs GlaxoSmithKline Pharmaceuticals Limited
Live data: 9 June 2026, 4:08 PM IST • Source: NSE and company filings
GlaxoSmithKline Pharmaceuticals Limited is the larger company by market capitalisation. Bafna Pharmaceuticals Limited shows a lower P/E and faster revenue growth, while GlaxoSmithKline Pharmaceuticals Limited shows a higher ROE, a higher dividend yield and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Side-by-side comparison of Bafna Pharmaceuticals Limited and GlaxoSmithKline Pharmaceuticals Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | BAFNAPH | GLAXO |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | BAFNAPH | GLAXO |
|---|---|---|
| Live Price | ₹174.58 | ₹2,552.8 |
| Day Change | -10% | 1.84% |
| Volume | 2.84 L | 87,820 |
| 52-Week High | ₹213.36 | ₹3,220 |
| 52-Week Low | ₹78.18 | ₹2,088.1 |
| Distance from 52W High | -18.18% | -20.72% |
Valuation
| Metric | BAFNAPH | GLAXO |
|---|---|---|
| Market Cap | ₹562 Cr | ₹43,336 Cr |
| P/E Ratio | 0x | 40.71x |
| P/B Ratio | 0x | 18.6x |
| EPS | ₹4.09 | ₹61.08 |
| Book Value | ₹38.54 | ₹133.85 |
| Dividend Yield | 0% | 2.3% |
Growth
| Metric | BAFNAPH | GLAXO |
|---|---|---|
| Revenue Growth (TTM YoY) | 15.4% | 2.1% |
| EPS Growth (TTM YoY) | 95% | 5.7% |
| Qtr Sales Growth | 30.9% | 2.15% |
| Qtr Profit Growth | 53.9% | 5.7% |
Profitability & Leverage
| Metric | BAFNAPH | GLAXO |
|---|---|---|
| ROE | 11.54% | 45.6% |
| ROCE | -3% | 61.4% |
| Net Margin | 7.37% | 27.29% |
| Operating Margin | 9.71% | 34.3% |
| Debt to Equity | 0.39x | 0.01x |
Shareholding
As of Mar 2026 • change vs previous quarter| Metric | BAFNAPH | GLAXO |
|---|---|---|
| Promoter Holding | 75% | 75% |
| FII Holding | 9.34% | 4.79%▲ 0.17 pp |
| DII Holding | 0% | 7.8%▲ 0.12 pp |
| Public Holding | 15.66% | 12.41%▼ 0.28 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Bafna Pharmaceuticals Limited and GlaxoSmithKline Pharmaceuticals Limited.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.